Prevalence of mental disorders in SLE patients: correlations with the disease activity and comorbid chronic conditions


Aim. To study effects of the disease activity and comorbid chronic conditions on the incidence of mental disorders in patients with systemic lupus erythematosus (SLE) treated in the State Institute of Rheumatology, RAMS.
Material and methods. A total of 115 patients with documented SLE (age 24-45 years, median 34 years, SLE duration 4-17, median 8 years) participated in the study. SLE activity was evaluated by SLEDAI scale, atherosclerosis - by ultrasonic arterial dopplerography, mental disorders - by psychological and psychic scales according to IDC-10.
Results. Mental disorders were detected in 76 of 115 (66%) patients: anxiety and depression (83%), depression episodes (40%), maladaptation (24%), generalized anxiety (10%), dysthymia (9%). Manifest cognitive disorders were seen in 7% of examinees. SLE patients with and without mental disorders did not differ by age, gender, SLE duration and activity, cumulative doses of glucocorticoids and cytotoxic drugs, but differed by diagnosed atherosclerosis (23 and 8%, respectively). All SLE patients with the history of myocardial infarction had mental disorders. SLE patients with antiphospholipid syndrome had mental disorders in 85%, while controls - in 49%.
Conclusion. Mental disorders are found frequently in SLE patients (66%). 83% of these disorders are anxiodepressive. Incidence of mental disorders in SLE patients do not correlate with age, gender, SLE duration and activity, doses of glucocorticoids and cytotoxic drugs, but correlate with comorbid diseases (atherosclerosis, myocardial infarction, acute cerebral attacks, antiphospholipid syndrome and Sjogren's syndrome.


  1. Purandare K. N., Wagle А. С., Parker S. R. Psychiatric morbidity in patients with systemic lupus erythematosus. Quart. J. Med. 1999; 92: 283-286.
  2. Hermosillo-Romo D., Brey R. L. Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Best Pract. Res. Clin. Rheumatol. 2002; 16 (2): 229-244.
  3. Levenson J. L. Psychiatric issues in rheumatology. Primary Psychiatry 2006; 13 (11); 23-27.
  4. Nived O., Sturfelt G., Liang M. H., De Pablo P. The ACR nomenclature for CNS lupus revisited. Lupus 2003; 12: 872-876.
  5. Hochberg M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematotosus. Arthritis Rheum. 1997; 40: 1725.
  6. Bombardier C., Gladman D. D., Urowitz M. B. et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthr. and Rheum. 1992; 35 (6): 630-640.
  7. Gladman D., Ginzler E., Goldsmith C. et al. Systemic Lupus International Collaborating Clinics: development of a damage index in systemic lupus erythematotosus. J. Rheumatol. 1992; 19: 1820-1821.
  8. Haward G., Sharrett A. R., Heiss G. et al. Carotid artery intima-media thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. Stroke 1993; 24: 1297-1304.
  9. Iannuzzi A., Michele M. D., Panico S. et al. Radical-trapping activity, blood pressure and carotid enlargement in women. Hypertension 2003; 41:289-296.
  10. Dentino A. N., Pieper C. F., Rao K. M. K et al. Association of interleukin-6 and other biologic variables with depression in older people living in the community. J. Am. Geriatr. Soc. 1999; 47: 6-11.
  11. Lutgendorf S. K., Garand L., Buckwalter K. Q. et al. Life stress, mood disturbance and elevated interleukin-6 in healthy older women. J. Gerontol. Biol. Sci. 1999; 54: M434-M439.
  12. Pasic J., Levy W. C., Sullivan M. D. Cytokines in depression and heart failure. Psychosom. Med. 2003; 65: 181-193.
  13. Pollmacher Т., Haack M., Schuld A. et al. Low levels of circulating inflammatory cytokines - do they affect human brain functions? Brain Behav. Immun. 2002; 16 (5): 525-532.
  14. Licinio J., Wong M. L. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999; 4 (4); 317-327.
  15. Smith R. S. The macrophage theory of depression (published erratum appears in Med Hypotheses 1991, 36, 178). Med. Hypothes. 1991; 35: 298-306.
  16. Medical conditions related to depression,
  17. Bisschop M. I., Kriegsman D. M. W., Beekman A. T. F., Deeg D. J. H. Chronic diseases and depression: the modifying role of psychosocial resources. Soc. Sci. Med., 2004; 59: 721-733.
  18. Appels A., Bar F. W., Bar J. et al. Inflammation, depressive symptomatology and coronary artery disease. Psychosom. Med. 2000; 62: 601-605.
  19. Denton F., Sharpe L., Schrieber L. Cognitive bias in systemic lupus erythematosus. Eur. J. Pain 2005; 9:1: 5-14.
  20. Brey R. L., Holliday S. L., Saklad A. R. et al. Neuropsychiatric syndromes in lupus. Neurology 2002; 58: 1214-1220.
  21. McLaurin E. Y., Holliday S. L., Williams P., Brey R. L. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 2005; 64 (2): 297-303.
  22. Whitelaw D. A., Spangenberg J. J., Rickman R. et al. Association between the antiphospholipid antibody syndrome and neuropsychological impairment in SLE. Lupus 1999; 8: 444-448.
  23. Mikdashi J., Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology 2004; 43: 1555-1560.
  24. Gerli R., Caponi L., Tincani A. et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematotosus: PROSPECTIVE evaluation in a large cohort of Italian patients. Rheumatology 2002; 41: 1357-1366.
  25. Segui J., Ramos-Casals M., Garcia-Carrasco M. et al. Psychiatric and psychosocial disorders in patients with systemic lupus erythematosus: a longitudinal study of active and inactive stages of the disease. Lupus 2000; 9 (8); 584-588.
  26. Feinglass E. J., Arnett F. C., Dorsch C. A. et al. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore) 1976; 55 (4): 323-329.
  27. Nery F. G., Borba E. F., Hatch J. P. et al. Major depressive disorder and disease activity in systemic lupus erythematosus. Compehens. Psychiatry 2007; 48 (1): 14-19.
  28. Jump R., Robinson M., Armstrong A. et al. Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression and perceived social support. J. Rheumatol. 2005; 32 (9): 1699-1705.
  29. Shortall E., Isenberg D., Newman S. P. Factors associated with mood and mood disorders in SLE. Lupus 1995; 4: 272-279.
  30. Lim L., Ron M. A., Ormerod I. E. et al. Psychiatric and neurological manifestations in systemic lupus erythematosus. Quart. Med. 1988; 66 (249): 27-38.
  31. Onda K., Kato S. A clinical study of psychopathology in systemic lupus erythematosus. Seishin Shinkeigku Zasshi 2000; 102 (7): 616-639.
  32. Wekking E. M., Vingerhoets A. J., Dam A. P. et al. Daily stressors and systemic lupus erythematosus: A longitudinal analysis - first findings. Psychother. and Psychosom. 1991; 55: 108-113.
  33. Peralta-Ramirez M. J. Alonso J. J., Godoy J. F. et al. The effects of daily stress and stressful life events on the clinical symptomatology of patients with lupus erythematosus. Psychosom. Med. 2004; 66; 788-794.
  34. Doria A., Rinaldi S., Ermani M. et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology. 2004; 43 (12): 1580-1586.
  35. Utset Т. О., Golden M., Siberry G. et al. Depressive symptoms in patients with systemic lupus erythematosus: association with central nervous system lupus and Sjogren's syndrome. J. Rheumatol. 1994; 21 (11): 2039-2045.
  36. Manzi S. Systemic lupus erythematosus: a model for atherogenesis? Rheumatology 2000; 39: 353-359.
  37. Попкова Т. В., Алекберова З. С., Александрова Е. Н. и др. Факторы риска кардиоваскулярных нарушений и атеросклероза при системной красной волчанке. Науч. практ. ревматол. 2004; 4: 10-14.

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies